FDA PMA FDA Class 3 Approved 🇺🇸 United States

Hybrid Stent Graft, Thoracic Aortic Lesion Treatment

PMA: P210006 · Supplement: S016 · Decision Jan 29, 2026
Classifications
1
FEI Numbers
0
Registration Numbers
0

Basic Information

Device Name
Hybrid Stent Graft, Thoracic Aortic Lesion Treatment
Trade Name
Thoraflex™ Hybrid
PMA Number
P210006
Supplement Number
S016
Device Class
FDA Class 3
Product Code
QSK
Generic Name
Hybrid stent graft, thoracic aortic lesion treatment
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
Approved
Decision Code
APPR
Decision Date
January 29, 2026
Date Received
December 30, 2025
Supplement Type
Special (Immediate Track)
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N

Advisory Committee Statement

an update to the lFU to include additional language regarding early imaging surveillance for patients at risk for intraluminal thrombosis

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
QSK Hybrid Stent Graft, Thoracic Aortic Lesion Treatment